208 related articles for article (PubMed ID: 33264454)
1. Frontline Science: OX40 agonistic antibody reverses immune suppression and improves survival in sepsis.
Unsinger J; Walton AH; Blood T; Tenney DJ; Quigley M; Drewry AM; Hotchkiss RS
J Leukoc Biol; 2021 Apr; 109(4):697-708. PubMed ID: 33264454
[TBL] [Abstract][Full Text] [Related]
2. Dose-dependent effect of anti-CTLA-4 on survival in sepsis.
Inoue S; Bo L; Bian J; Unsinger J; Chang K; Hotchkiss RS
Shock; 2011 Jul; 36(1):38-44. PubMed ID: 21368717
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-7 and anti-programmed cell death 1 antibody have differing effects to reverse sepsis-induced immunosuppression.
Shindo Y; Unsinger J; Burnham CA; Green JM; Hotchkiss RS
Shock; 2015 Apr; 43(4):334-43. PubMed ID: 25565644
[TBL] [Abstract][Full Text] [Related]
4. Ox40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo.
De Smedt T; Smith J; Baum P; Fanslow W; Butz E; Maliszewski C
J Immunol; 2002 Jan; 168(2):661-70. PubMed ID: 11777959
[TBL] [Abstract][Full Text] [Related]
5. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.
Guo Z; Wang X; Cheng D; Xia Z; Luan M; Zhang S
PLoS One; 2014; 9(2):e89350. PubMed ID: 24586709
[TBL] [Abstract][Full Text] [Related]
6. Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.
Jahan N; Talat H; Curry WT
Neuro Oncol; 2018 Jan; 20(1):44-54. PubMed ID: 29016879
[TBL] [Abstract][Full Text] [Related]
7. Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis.
Chang KC; Burnham CA; Compton SM; Rasche DP; Mazuski RJ; McDonough JS; Unsinger J; Korman AJ; Green JM; Hotchkiss RS
Crit Care; 2013 May; 17(3):R85. PubMed ID: 23663657
[TBL] [Abstract][Full Text] [Related]
8. The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis.
Garrison K; Hahn T; Lee WC; Ling LE; Weinberg AD; Akporiaye ET
Cancer Immunol Immunother; 2012 Apr; 61(4):511-21. PubMed ID: 21971588
[TBL] [Abstract][Full Text] [Related]
9. IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis.
Inoue S; Unsinger J; Davis CG; Muenzer JT; Ferguson TA; Chang K; Osborne DF; Clark AT; Coopersmith CM; McDunn JE; Hotchkiss RS
J Immunol; 2010 Feb; 184(3):1401-9. PubMed ID: 20026737
[TBL] [Abstract][Full Text] [Related]
10. OX40- and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ T cells to exit quiescence.
Buchan S; Manzo T; Flutter B; Rogel A; Edwards N; Zhang L; Sivakumaran S; Ghorashian S; Carpenter B; Bennett C; Freeman GJ; Sykes M; Croft M; Al-Shamkhani A; Chakraverty R
J Immunol; 2015 Jan; 194(1):125-133. PubMed ID: 25404365
[TBL] [Abstract][Full Text] [Related]
11. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
Linch SN; Kasiewicz MJ; McNamara MJ; Hilgart-Martiszus IF; Farhad M; Redmond WL
Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E319-27. PubMed ID: 26729864
[TBL] [Abstract][Full Text] [Related]
12. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis.
Chang K; Svabek C; Vazquez-Guillamet C; Sato B; Rasche D; Wilson S; Robbins P; Ulbrandt N; Suzich J; Green J; Patera AC; Blair W; Krishnan S; Hotchkiss R
Crit Care; 2014 Jan; 18(1):R3. PubMed ID: 24387680
[TBL] [Abstract][Full Text] [Related]
13. Restoration of T Cell function in multi-drug resistant bacterial sepsis after interleukin-7, anti-PD-L1, and OX-40 administration.
Thampy LK; Remy KE; Walton AH; Hong Z; Liu K; Liu R; Yi V; Burnham CD; Hotchkiss RS
PLoS One; 2018; 13(6):e0199497. PubMed ID: 29944697
[TBL] [Abstract][Full Text] [Related]
14. Polymicrobial Sepsis Increases Susceptibility to Chronic Viral Infection and Exacerbates CD8+ T Cell Exhaustion.
Condotta SA; Khan SH; Rai D; Griffith TS; Badovinac VP
J Immunol; 2015 Jul; 195(1):116-25. PubMed ID: 25980007
[TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of an agonistic aptamer against the T cell costimulatory receptor, OX40.
Pratico ED; Sullenger BA; Nair SK
Nucleic Acid Ther; 2013 Feb; 23(1):35-43. PubMed ID: 23113766
[TBL] [Abstract][Full Text] [Related]
16. OX40 Stimulation Enhances Protective Immune Responses Induced After Vaccination With Attenuated Malaria Parasites.
Othman AS; Franke-Fayard BM; Imai T; van der Gracht ETI; Redeker A; Salman AM; Marin-Mogollon C; Ramesar J; Chevalley-Maurel S; Janse CJ; Arens R; Khan SM
Front Cell Infect Microbiol; 2018; 8():247. PubMed ID: 30073152
[TBL] [Abstract][Full Text] [Related]
17. OX40 stimulation and PD-L1 blockade synergistically augment HBV-specific CD4 T cells in patients with HBeAg-negative infection.
Jacobi FJ; Wild K; Smits M; Zoldan K; Csernalabics B; Flecken T; Lang J; Ehrenmann P; Emmerich F; Hofmann M; Thimme R; Neumann-Haefelin C; Boettler T
J Hepatol; 2019 Jun; 70(6):1103-1113. PubMed ID: 30826436
[TBL] [Abstract][Full Text] [Related]
18. Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1.
Patera AC; Drewry AM; Chang K; Beiter ER; Osborne D; Hotchkiss RS
J Leukoc Biol; 2016 Dec; 100(6):1239-1254. PubMed ID: 27671246
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.
Moran AE; Polesso F; Weinberg AD
J Immunol; 2016 Sep; 197(6):2509-21. PubMed ID: 27503208
[TBL] [Abstract][Full Text] [Related]
20. Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo.
Redmond WL; Gough MJ; Weinberg AD
Eur J Immunol; 2009 Aug; 39(8):2184-94. PubMed ID: 19672905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
